Moreover, mice receiving plerixafor had an increased incidence of neurologic symptoms in association with BCR-ABL-expressing cell infiltration into the central nervous system, probably arising from a potent capacity of a CXCR4 antagonist to induce the egress of CML cells from bone marrow [82]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.